Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study

NCT05645536 is registered in ClinicalTrials.gov with Tolmar Inc. as lead sponsor.

NCT NCT05645536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05645536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study
Lead sponsor
Tolmar Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
December 28, 2022
Completion date
March 31, 2030
Enrollment
250 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer